A5264

A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy Versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource Limited Settings

Sponsors:
US National Institute of Allergy and Infectious Diseases (NIAID)
The National Cancer Institute (NCI)
National Institute of Dental Craniofacial Research (NIDCR)

Protocol Summary:
A5264 is a phase III, open-label, prospective, randomized study stratified by CD4+ lymphocyte cell count and antiretroviral (ART) history. This study will compare ART alone or with delayed chemotherapy to ART with immediate adjunctive chemotherapy for initial treatment of limited stage AIDS-related Karposi’s sarcoma (AIDS-KS) in chemotherapy and radiation naïve HIV-1 infected participants who are not currently receiving ART.

Years: 2012 – 2017

Investigator: Margaret Borok-Williams, MD, CHB, MMED

Location: Parirenyatwa CRS

ACTG

Completed Study

Publication:

Comments are closed.

Website by Canton Becker